Neurological Sciences

, Volume 32, Supplement 1, pp 95–98

Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies

  • Pietro Cortelli
  • Gianni Allais
  • Vincenzo Tullo
  • Chiara Benedetto
  • Dario Zava
  • Stefano Omboni
  • Gennaro Bussone
Symposium - Antimigraine Treatment: Preferences and Optimization

DOI: 10.1007/s10072-011-0551-2

Cite this article as:
Cortelli, P., Allais, G., Tullo, V. et al. Neurol Sci (2011) 32(Suppl 1): 95. doi:10.1007/s10072-011-0551-2

Abstract

The objective of the study is to systematically review the efficacy and safety of frovatriptan (F) versus rizatriptan (R), zolmitriptan (Z) and almotriptan (A), through a pooled analysis of three individual studies. 414 subjects with a history of migraine with or without aura (IHS criteria) were randomized to F 2.5 mg or R 10 mg (study 1), F 2.5 mg or Z 2.5 mg (study 2), and F 2.5 mg or A 12.5 mg (study 3). The studies had an identical multicenter, randomized, double blind, cross-over design, with each of the two treatment periods lasting not more than 3 months. The number of pain free (PF) and pain relief (PR) episodes at 2 h, and the number of sustained pain free (SPF) and recurrent episodes within the 48 h were the efficacy endpoints. 346 patients were included in the intention-to-treat analysis. Rate of PF episodes at 2 h was 30% with F and 34% with comparators (p = NS). PR episodes at 2 h were 55% for F and 59% for comparators (p = NS). SPF episodes at 48 h were also similar between the two groups (22% F vs. 21% comparators). Rate of recurrence was significantly (p < 0.001) lower under F (27 vs. 40% comparators). Drug-related adverse events were significantly (p < 0.05) less under F, particularly cardiovascular symptoms. Our systematic analysis of individual studies suggests that F has a similar immediate efficacy, but a more sustained effect and a better tolerability than R, Z and A.

Keywords

MigraineFrovatriptanRizatriptanZolmitriptanAlmotriptan

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Pietro Cortelli
    • 1
  • Gianni Allais
    • 2
  • Vincenzo Tullo
    • 3
  • Chiara Benedetto
    • 2
  • Dario Zava
    • 4
  • Stefano Omboni
    • 5
  • Gennaro Bussone
    • 3
  1. 1.Clinica Neurologica, Dipartimento di Scienze NeurologicheUniversità di BolognaBolognaItaly
  2. 2.Department of Gynecology and Obstetrics, Women’s Headache CenterUniversity of TorinoTurinItaly
  3. 3.Dipartimento di Neuroscienze ClinicheIstituto Nazionale Neurologico Carlo BestaMilanItaly
  4. 4.Istituto Lusofarmaco d’ItaliaMilanItaly
  5. 5.Italian Institute of TelemedicineVareseItaly